Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Research Article

Vol. 21 No. 1 (2023)

SARS-CoV-2 Epitope Presentation by Class II HLA Genotypes Common in North American Populations: A Proposed Computational Approach for Vaccine Efficacy Evaluation

DOI
https://doi.org/10.26443/mjm.v21i1.907
Submitted
November 7, 2021
Published
2022-10-06

Abstract

Background: Human Leukocyte Antigen (HLA) gene polymorphisms between ethnic groups have been shown to play a role in the heterogeneity of response to SARS-CoV-2, in terms of COVID-19 disease severity and susceptibility, in addition to socioeconomic factors. It was predicted that this finding may extend to vaccine responsiveness.

Purpose: To the best of our knowledge, this study was the first that aimed to predict and evaluate the effectiveness of four COVID-19 vaccines across North American ethnic groups, in terms of their ability to trigger CD4+ T cell help, based on class II HLA allele frequencies.

Methods: Various databases including the Immune Epitope Database (IEDB) were used in this computational approach. The number of peptide-HLA high-affinity pairs between the most common HLA II haplotypes and SARS-CoV-2 peptides in various vaccine types were retrieved and compared between ethnicities. From this, the efficiency of antigen presentation to CD4+ T cells was evaluated, a crucial component in the context of vaccination for cellular immunity and support in antibody generation.

Results: Multiple discrepancies in vaccine effectiveness for ethnic minorities relative to the Caucasian group, overrepresented in vaccine clinical trials, were highlighted. Recommendations were issued in terms of which vaccine types could be most effective for particular ethnicities.

Conclusion: There exists a genetic basis for differential responses to vaccines among ethnic groups in North America. However, given the multifactorial nature of vaccine responsiveness and limitations of computational methods, this study offers future research directions to undertake before the findings can be transferred to clinical and public health settings.

References

  1. Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12(3):254.
  2. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861–80.
  3. COVID-19 Vaccine Tracker [Internet]. Montreal (QC): McGill University Interdisciplinary Initiative in Infection and Immunity; 2021 [cited 2021 Mar 2021]. Available from: https://covid19.trackvaccines.org/vaccines/
  4. Draft landscape and tracker of COVID-19 candidate vaccines [Internet]. Geneva (Switzerland): World Health Organization; 2021 [updated 2021 Jun 4; cited 2021 Mar 1]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
  5. Huang Q, Yan J. SARS-CoV-2 virus: Vaccines in development. Fundamental Research. 2021;1(2):131–8.
  6. Zelba H, Worbs D, Harter J, Pieper N, Kyzirakos-Feger C, Kayser S, et al. A Highly Specific Assay for the Detection of SARS-CoV-2–Reactive CD4+ and CD8+ T Cells in COVID-19 Patients. J Immunol. 2020;206(3):580-7.
  7. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181(7):1489–501.
  8. COVID-19 HLA and Immunogenetics Consortium. Why HLA? [Internet]. Mt. Laurel (NJ): HLA | COVID-19 American Society for Histocompatibility and Immunogenetics; date unknown [cited 2021 Mar 1]. Available from: http://www.hlacovid19.org/whyhla/
  9. Cruz-Tapias P, Castiblanco J, Anaya JM. Major histocompatibility complex: Antigen processing and presentation. In: Autoimmunity: From Bench to Bedside [Internet]. Bogota (Colombia): El Rosario University Press; 2013 [cited 2021 Mar 1]. Available from NCBI: https://www.ncbi.nlm.nih.gov/books/NBK459467/
  10. Pisanti S, Deelen J, Gallina AM, Caputo M, Citro M, Abate M, et al. Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19. J Transl Med. 2020;18(1)352.
  11. Novelli A, Andreani M, Biancolella M, Liberatoscioli L, Passarelli C, Colona VL, et al. HLA allele frequencies and susceptibility to COVID ‐19 in a group of 99 Italian patients. HLA. 2020;96(5):610–4.
  12. Poulton K, Wright P, Hughes P, Savic S, Welberry Smith M, Guiver M, et al. A role for human leucocyte antigens in the susceptibility to SARS‐Cov‐2 infection observed in transplant patients. Int J Immunogenet. 2020;47(4)324–8.
  13. Amoroso A, Magistroni P, Vespasiano F, Amorosa A, Bellino S, Puoti F, et al. HLA and AB0 Polymorphisms Influence SARS-CoV-2 Infection and COVID-19 Severity. Transplantation. 2021;105(1):193–200.
  14. Littera R, Campagna M, Deidda S, Angioni G, Cipri S, Melis M, et al. Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. Front Immunol. 2020;11.
  15. Kolin DA, Kulm S, Christos PJ, Elemento O. Clinical, regional, and genetic characteristics of Covid-19 patients from UK Biobank. PloS One. 2020;15(11):e0241264.
  16. Ahmadi Y, Shahsavar F, Tehrani-Banihashemi A, Elmi M, Ahmadi P, Sohrabpour S, et al. An ecological modeling on the adjusted effects of socioeconomic determinants and HLA- DRB1 alleles in fatality of COVID-19 during the early phase of epidemics in a group of countries. ResearchGate In press. 2020;doi:10.13140/RG.2.2.16393.26727.
  17. Barquera R, Collen E, Di D, Buhler S, Teixeira J, Llamas B, et al. Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide. HLA. 2020;96(3): 277–98.
  18. Copley HC, Gragert L, Leach AR, Kosmoliaptsis V. Influence of HLA class II polymorphism on predicted cellular immunity against SARS-CoV-2 at the population and individual level. Frontiers Immunol. 2021;12.
  19. He J, Huang F, Zhang J, Chen Q, Zheng Z, Zhou Q, et al. Vaccine design based on 16 epitopes of SARS‐CoV‐2 spike protein. J Med Virol. 2020;93(4):2115–31.
  20. Liu G, Carter B, Bricken T, Jain S, Viard M, Carrington M, et al. Computationally Optimized SARS-CoV-2 MHC Class I and II Vaccine Formulations Predicted to Target Human Haplotype Distributions. Cell Syst. 2020;11(2):131-44.
  21. Risk for COVID-19 Infection, Hospitalization, and Death By Race/Ethnicity [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2020 [updated 2021 May 26; cited 2021 Mar 1]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html
  22. Chin-Hong P, Alexander KM, Haynes N, Albert MA. Pulling at the heart: COVID-19, race/ethnicity and ongoing disparities. Nat Rev Cardiol. 2020;17(9):533–5.
  23. Drucker DJ. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. Cell Metab. 2021;33(3):479–98.
  24. Kwok S, Adam S, Ho JH, Iqbal Z, Turkington P, Razvi S, et al. Obesity: A critical risk factor in the COVID ‐19 pandemic. Clin Obes. 2020;10(6).
  25. Mangum VE. COVID-19: a Review of the Literature Regarding African American Patient Outcomes. J Afr Am Stud. 2021;25(1)152–61.
  26. Flores LE, Frontera WR, Andrasik MP, del Rio C, Mondríguez-González A, Price SA, et al. Assessment of the Inclusion of Racial/Ethnic Minority, Female, and Older Individuals in Vaccine Clinical Trials. JAMA Netw Open. 2021;4(2):e2037640.
  27. Confirmed cases of COVID-19 [Internet]. Gatineau (QC): Indigenous Services Canada; 2020 [updated 2021 Jun 4; cited 2021 Mar 1]. Available from: https://www.sacisc.gc.ca/eng/1598625105013/1598625167707
  28. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis. Int J Infect Dis. 2022;114:252–60.
  29. Hwang W, Lei W, Katritsis NM, MacMahon M, Chapman K, Han N. Current and prospective computational approaches and challenges for developing COVID-19 vaccines. Adv Drug Deliv Rev. 2021;172:249–74.
  30. Liu G, Carter B, Gifford DK. Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and Their Augmentation by Compact Peptide Sets. Cell Syst. 2020;12(1):102–7.
  31. Gonzalez-Galarza FF, McCabe A, Santos EJMdos, Jones J, Takeshita L, Ortega-Rivera ND, et al. Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res. 2020; 48(D1):D783–D788.
  32. R: A language and environment for statistical computing [Internet]. Vienna (Austria): R Core Team; date unknown [cited 2021 Mar 1]. Available from: https://www.R-project.org/
  33. Barquera R, Zuniga J, Flores-Rivera J, Corona T, Penman BS, Hernández-Zaragoza DI, et al. Diversity of HLA Class I and Class II blocks and conserved extended haplotypes in Lacandon Mayans. Sci Rep. 2020;10(1):3248.
  34. Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, et al. HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk: Analysis of the Type 1 Diabetes Genetics Consortium Families. Diabetes. 2008;57(4):1084–92.
  35. Gao X, Zimmet P, Serjeantson SW. HLA-DR,DQ sequence polymorphisms in Polynesians, Micronesians, and Javanese. Hum Immunol. 1992;34(3):153–61.
  36. González-Quezada BA, Creary LE, Munguia-Saldaña AJ, Flores-Aguilar H, Fernández-Viña MA, Gorodezky C. Exploring the ancestry and admixture of Mexican Oaxaca Mestizos from Southeast Mexico using next-generation sequencing of 11 HLA loci. Human Immunol. 2019;80(3):157–62.
  37. Just JJ, King M-C, Thomson G, Klitz W. African-American HLA class II allele and haplotype diversity. Tissue Antigens. 1997;49(5): 547–55.
  38. Kwok J, Tang WH, Chu WK, Liu Z, Yang W, Lee CK, et al. HLA-DQB1, -DQA1, -DPB1, and -DPA1 genotyping and haplotype frequencies for a Hong Kong Chinese population of 1064 individuals. Human Immunol. 2020;81(1):3–5.
  39. Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, et al. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. 2018;47(D1):D339–D343.
  40. Clark K, Karsch-Mizrachi I, Lipman DJ, Ostell J, Sayers EW. GenBank. Nucleic Acids Res. 2016;44(D1):D67-D72.
  41. Split FASTA [Internet]. Edmonton (AB): Sequence Manipulation Suite; date unknown [updated 2020 Jun 14; cited 2021 Mar 1]. Available from: https://www.bioinformatics.org/sms2/split_fasta.html
  42. Fleri W, Paul S, Dhanda SK, Mahajan S, Xu X, Peters B, et al. The Immune Epitope Database and Analysis Resource in Epitope Discovery and Synthetic Vaccine Design. Frontiers Immunol. 2017;8:278.
  43. Paul S, Lindestam Arlehamn CS, Scriba TJ, Dillon MBC, Oseroff C, Hinz D, et al. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. J Immunol Methods. 2015;422:28–34.
  44. Sohail MS, Ahmed SF, Quadeer AA, McKay MR. In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives. Adv Drug Deliv Rev. 2021;171:29–47.
  45. Devaux CA, Rolain J-M, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020;53(3):425–435.
  46. Mayoral EP-C, Hernández-Huerta MT, Pérez-Campos Mayoral L, Matias-Cervantes CA, Mayoral-Andrade G, Barrios LÁ, et al. Factors related to asymptomatic or severe COVID-19 infection. Med Hypotheses. 2020;144:110296.

Downloads

Download data is not yet available.